Clinigen ‘definitely not expecting a slowdown in H2’ as acquisitions are bedded in
March 2, 2016 12:27 pm
3 March 2016: Clinigen deputy CEO Shaun Chilton, tells IG that Clinigen will remain a cash generating business and recent acquisitions will only serve to drive Clinigen forward. On the Brexit vote, Shaun says that Clinigen would be better served if the UK remained in the EU. For the second half the company has a considerable cash pile and will make acquisitions as it sees fit, but will concentrate on bedding in its new businesses. Clinigen also told investors that it had done another acquisition with the purchase of Totect from American firm Biocodex. Shaun says that Clinigen expects the acquisition to be beneficial in the first half of next year.
3 March 2016: Clinigen deputy CEO Shaun Chilton, tells IG that Clinigen will remain a cash generating business and recent acquisitions will only serve to drive Clinigen forward. On the Brexit vote, Shaun says that Clinigen would be better served if the UK remained in the EU.
For the second half the company has a considerable cash pile and will make acquisitions as it sees fit, but will concentrate on bedding in its new businesses.
Clinigen also told investors that it had done another acquisition with the purchase of Totect from American firm Biocodex. Shaun says that Clinigen expects the acquisition to be beneficial in the first half of next year.
Related Posts: